Considering the ability of METCAM/MUC18 as a driver for the malignant progression of the cancer, after extensive follow-up checking of our patients in future, we also believe that METCAM/MUC18 has the high potential to be used for differentiating the indolent prostate cancers from aggressive ones in clinics. The gene discussed is MCAM; the disease is cancer.